Table 4.
Variants per oncogene/tumor-suppressor gene that were detected in all sequenced CTCs within a subject (total number of variants per gene were combined from all seven subjects; variants detected in ≥1 subject were counted once only, adding up to a total of 598 variants).
| Gene | Number of Variants |
|---|---|
| NF1 | 69 |
| BRCA2 | 33 |
| PTCH1 | 33 |
| NF2 | 27 |
| ATM | 25 |
| EGFR | 24 |
| ERBB3 | 24 |
| PIK3CA | 19 |
| APC | 17 |
| BRCA1 | 17 |
| RB1 | 13 |
| SMARCB1 | 13 |
| TP53 | 13 |
| CDH1 | 12 |
| CSF1R | 11 |
| NOTCH1 | 11 |
| SMO | 11 |
| TERT | 11 |
| ABL1 | 10 |
| MLH1 | 10 |
| EZH2 | 9 |
| FGFR2 | 9 |
| SMAD4 | 9 |
| DNMT3A | 8 |
| FBXW7 | 8 |
| MTOR | 8 |
| CTNNB1 | 7 |
| ERBB2 | 7 |
| HNF1A | 7 |
| KIT | 7 |
| PIK3R1 | 7 |
| PTEN | 7 |
| ALK | 6 |
| CDKN2A | 6 |
| PTPN11 | 6 |
| ERBB4 | 5 |
| JAK2 | 5 |
| JAK3 | 5 |
| RET | 5 |
| BRAF | 4 |
| KRAS | 4 |
| LOC100507346 | 4 |
| STK11 | 4 |
| VHL | 4 |
| FGFR3 | 3 |
| FLT3 | 3 |
| HRAS | 3 |
| IDH1 | 3 |
| IDH2 | 3 |
| KDR | 3 |
| MET | 3 |
| NPM1 | 3 |
| TSC1 | 3 |
| AKT1 | 2 |
| FGFR1 | 2 |
| GNAQ | 2 |
| GNAS | 2 |
| NRAS | 2 |
| PDGFRA | 2 |
| ATM; C11orf65 | 1 |
| FBXW7-AS1 | 1 |
| GNA11 | 1 |
| MAP2K1 | 1 |
| MSH6 | 1 |